Day Ronald W, Clement Parker W, Hersh Aimee O, Connors Susan M, Sumner Kelli L, Best D Hunter, Alashari Mouied
University of Utah Department of Pediatrics, 81 North Mario Capecchi Drive, Salt Lake City, UT 84113, USA.
University of Utah Department of Pathology, 15 North Medical Drive, Suite 1100, Salt Lake City, UT 84132, USA.
Respir Med Case Rep. 2016 Dec 29;20:82-86. doi: 10.1016/j.rmcr.2016.12.007. eCollection 2017.
Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis are rare forms of pulmonary vascular disease. We report two cases of affected children who had evidence of pulmonary hypertension 3-5 years before developing radiographic findings of pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. Both patients experienced a moderate decrease in pulmonary arterial pressure during acute vasodilator testing. Both patients experienced an improvement in six-minute walk performance without an increase in pulmonary edema when treated with targeted therapy for pulmonary hypertension. In some patients, pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis may progress slowly over a period of months to years. A favorable acute vasodilator response may identify patients who will tolerate, and demonstrate transient clinical improvement with, medical therapy.
肺静脉闭塞病和肺毛细血管瘤病是罕见的肺血管疾病形式。我们报告了两例患病儿童,他们在出现肺静脉闭塞病或肺毛细血管瘤病的影像学表现之前3 - 5年就有肺动脉高压的证据。两名患者在急性血管扩张剂测试期间肺动脉压均有适度下降。当接受肺动脉高压靶向治疗时,两名患者的六分钟步行能力均有改善,且未出现肺水肿加重。在一些患者中,肺静脉闭塞病和肺毛细血管瘤病可能在数月至数年的时间里缓慢进展。良好的急性血管扩张剂反应可能有助于识别那些能够耐受药物治疗并在治疗中出现短暂临床改善的患者。